Trial Profile
Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Heart Transplant
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 24 Jun 2022
Price :
$35
*
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Proof of concept; Therapeutic Use
- 05 May 2021 Status changed from recruiting to discontinued because protocol transitioned to standard of care, no funding available to support research work.
- 07 Apr 2021 Planned number of patients changed from 30 to 50.
- 01 Mar 2019 Planned number of patients changed from 10 to 30.